The Framingham Study: A Family Affair

In the 1990s, anyone tuning in to a television news program or opening a popular magazine in the United States can learn about the dangers of such heart risk factors as hypertension, high cholesterol, and cigarette smoking. But until the early 1950s, these factors were not identified as precursors of heart disease. "The Framingham study put into numbers what was only assumed or thought at the time," says Marvin Moser, a clinical professor of medicine at Yale University School of Medicine. "And

Written byLisa Holland
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

When the study began in 1948, about 10,000 of Framingham's 28,000 residents fell within the study's preferred age range of 30 to 62 years (the age group shown to precede that at risk of developing heart disease). From this group, 5,209 men and women agreed to physical exams every two years for the next 20 years. Of these, 5,127 were free of coronary heart disease at the start of the study. At each biennial exam, in addition to a basic heart check-up, the researchers performed a special study. For instance, at Exam 4, the degree of obesity was determined; at Exam 11, fasting lipids were measured.

In 1971, the children of the original cohort, as well as their spouses, were asked to participate in a new heart study. The Offspring Study included 5,135 participants, aged 20 to 70. According to William B. Kannel, former study director, the Offspring Study was ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies